(VIANEWS) – Provident Financial Services (PFS), BanColombia S.A. (CIB), Genmab (GMAB) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Provident Financial Services (PFS)
73.6% sales growth and 9.46% return on equity
Provident Financial Services, Inc. operates as the bank holding company for Provident Bank that provides various banking products and services to individuals, families, and businesses in the United States. Its deposit products include savings, checking, interest-bearing checking, money market deposit, and certificate of deposit accounts, as well as IRA products. The company's loan portfolio comprises commercial real estate loans that are secured by properties, such as multi-family apartment buildings, office buildings, and retail and industrial properties; commercial business loans; fixed-rate and adjustable-rate mortgage loans collateralized by one- to four-family residential real estate properties; commercial construction loans; and consumer loans consisting of home equity loans, home equity lines of credit, marine loans, personal loans and unsecured lines of credit, and auto and recreational vehicle loans. It also offers cash management, remote deposit capture, payroll origination, escrow account management, and online and mobile banking services; and business credit cards. In addition, the company provides wealth management services comprising investment management, trust and estate administration, financial planning, tax compliance and planning, and private banking. Further, it sells insurance and investment products, including annuities; operates as a real estate investment trust for acquiring mortgage loans and other real estate related assets; and manages and sells real estate properties acquired through foreclosure. The company was founded in 1839 and is headquartered in Jersey City, New Jersey.
Earnings Per Share
As for profitability, Provident Financial Services has a trailing twelve months EPS of $2.01.
PE Ratio
Provident Financial Services has a trailing twelve months price to earnings ratio of 8.84. Meaning, the purchaser of the share is investing $8.84 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.46%.
Dividend Yield
As stated by Morningstar, Inc., the next dividend payment is on Nov 8, 2023, the estimated forward annual dividend rate is 0.96 and the estimated forward annual dividend yield is 5.43%.
Yearly Top and Bottom Value
Provident Financial Services’s stock is valued at $17.76 at 15:22 EST, way under its 52-week high of $24.58 and way higher than its 52-week low of $13.43.
Volume
Today’s last reported volume for Provident Financial Services is 668654 which is 31.73% above its average volume of 507559.
Moving Average
Provident Financial Services’s worth is above its 50-day moving average of $16.84 and higher than its 200-day moving average of $16.56.
2. BanColombia S.A. (CIB)
56.1% sales growth and 16.94% return on equity
Bancolombia S. A. provides various banking products and services to individual and corporate customers in Colombia, Panama, Puerto Rico, El Salvador, Costa Rica, and Guatemala. The company operates through nine segments: Banking Colombia, Banking Panama, Banking El Salvador, Banking Guatemala, Trust, Investment Banking, Brokerage, International Banking, and All Other. It offers checking and savings accounts, fixed term deposits, and investment products; trade financing, loans funded by domestic development banks, working capital loans, credit cards, personal and vehicle loans, payroll loans, and overdrafts; financial support to real estate developers and mortgages for individuals and companies; and financial and operating leasing services. The company also provides hedging instruments, including futures, forwards, options, and swaps; and brokerage, investment advisory, and private banking services, including selling and distributing equities, futures, foreign currencies, fixed income securities, mutual funds, and structured products. In addition, it offers cash management services; foreign currency transaction services; life, auto, commercial, and homeowner's insurance products; and online and computer banking services. Further, the company provides investment banking services comprising project and acquisition finance, debt and equity capital markets, principal investments, M&A, restructurings, and structured financing; money market accounts, mutual and pension funds, private equity funds, payment trust, custody, and corporate trust; and digital banking platform, transportation, securities brokerage, maintenance and remodeling, advertising and marketing, and outsourcing services, as well as credit cards. As of December 31, 2020, it operated 1,057 branches; 18,631 banking correspondents; 535 PAMs; 215 kiosks in El Salvador and 137 in Colombia; and 6,124 automatic teller machines. Bancolombia S.A. was incorporated in 1945 and is headquartered in MedellÃn, Colombia.
Earnings Per Share
As for profitability, BanColombia S.A. has a trailing twelve months EPS of $6.69.
PE Ratio
BanColombia S.A. has a trailing twelve months price to earnings ratio of 4.66. Meaning, the purchaser of the share is investing $4.66 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 16.94%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 0.1%, now sitting on 20.69T for the twelve trailing months.
Volume
Today’s last reported volume for BanColombia S.A. is 148817 which is 42.74% below its average volume of 259916.
Dividend Yield
According to Morningstar, Inc., the next dividend payment is on Dec 26, 2023, the estimated forward annual dividend rate is 2.86 and the estimated forward annual dividend yield is 9.05%.
3. Genmab (GMAB)
41.6% sales growth and 14.87% return on equity
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company also develops Teclistamab, which is in Phase 2 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
Earnings Per Share
As for profitability, Genmab has a trailing twelve months EPS of $0.94.
PE Ratio
Genmab has a trailing twelve months price to earnings ratio of 29.51. Meaning, the purchaser of the share is investing $29.51 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 14.87%.
4. Intercontinental Exchange (ICE)
20.4% sales growth and 10.38% return on equity
Intercontinental Exchange, Inc., together with its subsidiaries, engages in the provision of market infrastructure, data services, and technology solutions for financial institutions, corporations, and government entities in the United States, the United Kingdom, the European Union, Singapore, India, Abu Dhabi, Israel, and Canada. It operates through three segments: Exchanges, Fixed Income and Data Services, and Mortgage Technology. The company operates regulated marketplaces for listing, trading, and clearing an array of derivatives contracts and financial securities, such as commodities, interest rates, foreign exchange, and equities, as well as corporate and exchange-traded funds; and trading venues, including regulated exchanges and clearing houses. It also offers energy, agricultural and metals, and financial futures and options; and cash equities and equity options, and over-the-counter and other markets, as well as listings and data and connectivity services. In addition, the company provides fixed income data and analytic, fixed income execution, CDS clearing, and other multi-asset class data and network services. Further, it offers proprietary and comprehensive mortgage origination platform, which serves residential mortgage loans; closing solutions that provides customers connectivity to the mortgage supply chain and facilitates the secure exchange of information; data and analytics services; and Data as a Service for lenders to access data and origination information. Intercontinental Exchange, Inc. was founded in 2000 and is headquartered in Atlanta, Georgia.
Earnings Per Share
As for profitability, Intercontinental Exchange has a trailing twelve months EPS of $4.32.
PE Ratio
Intercontinental Exchange has a trailing twelve months price to earnings ratio of 31.44. Meaning, the purchaser of the share is investing $31.44 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.38%.
Sales Growth
Intercontinental Exchange’s sales growth is 24.4% for the present quarter and 20.4% for the next.
Yearly Top and Bottom Value
Intercontinental Exchange’s stock is valued at $135.82 at 15:22 EST, higher than its 52-week high of $129.96.
Moving Average
Intercontinental Exchange’s value is way higher than its 50-day moving average of $122.67 and way higher than its 200-day moving average of $114.11.
Revenue Growth
Year-on-year quarterly revenue growth grew by 10.6%, now sitting on 7.55B for the twelve trailing months.
Previous days news about Intercontinental Exchange(ICE)
- According to Zacks on Monday, 5 February, "Intercontinental Exchange Inc. price-eps-surprise | Intercontinental Exchange Inc. Quote"
5. Oceaneering International (OII)
19.4% sales growth and 14.48% return on equity
Investors might want to look at some better-ranked stocks in the energy sector, such as VAALCO Energy (EGY Quick QuoteEGY – Free Report) , Oceaneering International (OII Quick QuoteOII – Free Report) and Harbour Energy (HBRIY Quick QuoteHBRIY – Free Report) . , While VAALCO and Oceaneering International currently sport a Zacks Rank #1 (Strong Buy) each, Harbour Energy holds a Zacks Rank #2 (Buy).
Oceaneering International, Inc. provides engineered services and products, and robotic solutions to the offshore energy, defense, aerospace, manufacturing, and entertainment industries worldwide. The company's Subsea Robotics segment provides remotely operated vehicles (ROVs) for drill support and vessel-based services, including subsea hardware installation, construction, pipeline inspection, survey and facilities inspection, maintenance, and repair. This segment also offers ROV tooling, and survey services, such as hydrographic survey and positioning services, as well as autonomous underwater vehicles for geoscience. Its Manufactured Products segment provides distribution and connection systems, including production control umbilicals and field development hardware, pipeline connection, and repair systems to the energy industry; and autonomous mobile robots technology and entertainment systems to various industries. The company's Offshore Projects Group segment offers subsea installation and intervention, including riserless light well intervention services and inspection, and maintenance and repair services; installation and workover control systems, and ROV workover control systems; diving services; project management and engineering; and drill pipe riser services and systems, and wellhead load relief solutions. Its Integrity Management & Digital Solutions segment provides asset integrity management; software and analytical solutions for the bulk cargo maritime industry; and software, digital, and connectivity solutions for the energy industry. The company's Aerospace and Defense Technologies segment offers government services and products, including engineering and related manufacturing in defense and space exploration activities to U.S. government agencies and their prime contractors. Oceaneering International, Inc. was founded in 1964 and is headquartered in Houston, Texas.
Earnings Per Share
As for profitability, Oceaneering International has a trailing twelve months EPS of $0.75.
PE Ratio
Oceaneering International has a trailing twelve months price to earnings ratio of 28.57. Meaning, the purchaser of the share is investing $28.57 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 14.48%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 13.5%, now sitting on 2.31B for the twelve trailing months.
Previous days news about Oceaneering International(OII)
- Oceaneering international (oii) increases despite market slip: here's what you need to know. According to Zacks on Monday, 5 February, "Valuation is also important, so investors should note that Oceaneering International has a Forward P/E ratio of 13.29 right now. ", "In the latest market close, Oceaneering International (OII Quick QuoteOII – Free Report) reached $20.22, with a +0.3% movement compared to the previous day. "
- Oceaneering international (oii) rises but trails market: what investors should know. According to Zacks on Tuesday, 6 February, "Investors will be eagerly watching for the performance of Oceaneering International in its upcoming earnings disclosure. ", "The most recent trading session ended with Oceaneering International (OII Quick QuoteOII – Free Report) standing at $20.25, reflecting a +0.15% shift from the previouse trading day’s closing. "
6. Magna International (MGA)
14% sales growth and 9.73% return on equity
Magna International Inc. designs, engineers, and manufactures components, assemblies, systems, subsystems, and modules for original equipment manufacturers of vehicles and light trucks worldwide. It operates through four segments: Body Exteriors & Structures, Power & Vision, Seating Systems, and Complete Vehicles. The Body Exteriors & Structures segment provides body and chassis, exterior, and roof systems, as well as battery enclosures and engineering and testing services, including fascia and trims, front end modules, integration panels, liftgate modules, active aerodynamics, engineered glass, running boards, truck bed access products, breakthrough lightings, quarter windows, encapsulated glasses, and side doors. The Power & Vision segment offers ?electric drive systems and components, such as emotors, inverters, onboard chargers, gearboxes, and e-clutch; dedicated hybrid drives, dual and hybrid dual clutch, and manual transmissions; AWD/4WD products and rear drive modules; transmission, driveline components, and ICE; engineering services; advanced driver assistance systems sensors and, and electronic control units; interior and exterior mirrors, camera and driver monitoring systems and electronics, actuators, door handles, and overhead consoles; forward, rear, and auxiliary lighting products; latching, door modules, window, power closure, and hinges and wire forming systems; and modular and textile folding roofs, and hard and soft tops. The Seating Systems segment provides seat structures, mechanism and hardware solutions, and foam and trim products. The Complete Vehicles segment offers vehicle engineering and manufacturing services. The company also designs, engineers, and manufactures tooling products. Magna International Inc. was founded in 1957 and is headquartered in Aurora, Canada.
Earnings Per Share
As for profitability, Magna International has a trailing twelve months EPS of $3.62.
PE Ratio
Magna International has a trailing twelve months price to earnings ratio of 16.19. Meaning, the purchaser of the share is investing $16.19 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.73%.
Dividend Yield
According to Morningstar, Inc., the next dividend payment is on Nov 15, 2023, the estimated forward annual dividend rate is 1.84 and the estimated forward annual dividend yield is 3.23%.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is 62.6% and 35.1%, respectively.
Volume
Today’s last reported volume for Magna International is 988660 which is 8% below its average volume of 1074660.
7. Bruker Corporation (BRKR)
7% sales growth and 29.32% return on equity
Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States and internationally. The company operates through three segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. It offers life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips, and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical, and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. Bruker Corporation has a collaboration with Newomics Inc. on a LC-MS platform for drug discovery. The company was incorporated in 1991 and is headquartered in Billerica, Massachusetts.
Earnings Per Share
As for profitability, Bruker Corporation has a trailing twelve months EPS of $2.16.
PE Ratio
Bruker Corporation has a trailing twelve months price to earnings ratio of 33.32. Meaning, the purchaser of the share is investing $33.32 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 29.32%.
Moving Average
Bruker Corporation’s value is higher than its 50-day moving average of $69.40 and above its 200-day moving average of $69.07.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Bruker Corporation’s EBITDA is 65.58.
